ClinicalTrials.gg
CompletedNCT00143143Updated Jul 24, 2006

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

A Phase 3 interventional study of Pregabalin in Epilepsies, Partial and Epilepsy, Complex Partial, sponsored by Pfizer. Completed at 47 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-07-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
9th of 18
300 · median 244
Started
2001
the only one that year
Phase 3
12 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
7 of 18
Pfizer

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 9th largest by enrollment, is the only one that started in 2001, is one of 12 in phase 3, and was the 1st registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.

03

Conditions studied

  • Epilepsies, Partial
  • Epilepsy, Complex Partial

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have met the inclusion criteria for Study 1008-157, have received double-blind study medication, and wish to receive open-label pregabalin
  • Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening
  • Be currently taking 1 to 3 AEDs.

Exclusion criteria

Exclusion Criteria:

  • Have a treatable cause of seizures
  • Experienced a serious adverse event during Study 1008-157 which was determined to be possibly related to study medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety assessments are performed at quarterly visits up until the study is closed.

Secondary outcomes

  1. Seizure frequency is assessed throughout the study until the study is closed.

07

Study locations

47 sites
  • Pfizer Investigational Site
    Innsbruck, A6020, Austria
  • Pfizer Investigational Site
    Mauer Bei Amstetten, 3362, Austria
  • Pfizer Investigational Site
    St Polten, A3100, Austria
  • Pfizer Investigational Site
    Wien, 1090, Austria
  • Pfizer Investigational Site
    Calgary, Alberta T2N 2T9, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5G 0B7, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Pfizer Investigational Site
    Barrie, Ontario L4M 4S5, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 5A5, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • Pfizer Investigational Site
    Trois Rivieres, Quebec G8Z 4K4, Canada
  • Pfizer Investigational Site
    Marseille, Cedex 05 13005, France
  • Pfizer Investigational Site
    Paris, Cedex 13 75651, France
  • Pfizer Investigational Site
    Montpellier, Cedex 5 34295, France
  • Pfizer Investigational Site
    Lille, Cedex 59037, France
  • Pfizer Investigational Site
    Rennes, Cedex 35033, France
  • Pfizer Investigational Site
    Colomiers, 31770, France
  • Pfizer Investigational Site
    Dommartin Les Toul, 54201, France
  • Pfizer Investigational Site
    Marseille Cedex 09, 13274, France
  • Pfizer Investigational Site
    Strasbourg, 67091, France
  • Pfizer Investigational Site
    Berlin, 10365, Germany
  • Pfizer Investigational Site
    Berlin, 13353, Germany
  • Pfizer Investigational Site
    Bielefeld, 33617, Germany
  • Pfizer Investigational Site
    Bonn, 53127, Germany
  • Pfizer Investigational Site
    Essen, 45147, Germany
  • Pfizer Investigational Site
    Frankfurt, 60528, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Goettingen, D-37075, Germany
  • Pfizer Investigational Site
    Kehl, 77694, Germany
  • Pfizer Investigational Site
    Marburg, 35039, Germany
  • Pfizer Investigational Site
    ULM, 89075, Germany
  • Pfizer Investigational Site
    Firenze, 50122, Italy
  • Pfizer Investigational Site
    Perugia, 06123, Italy
  • Pfizer Investigational Site
    Pisa, 56126, Italy
  • Pfizer Investigational Site
    Siena, 53100, Italy
  • Pfizer Investigational Site
    Vilnius, 2600, Lithuania
  • Pfizer Investigational Site
    Vilnius, LT-2600, Lithuania
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Donostia-San Sebastian, 20014, Spain
  • Pfizer Investigational Site
    Gerona, 17007, Spain
  • Pfizer Investigational Site
    Madrid, 28034, Spain
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Glascow, Scotland G11 6NT, United Kingdom
  • Pfizer Investigational Site
    Fazakerley, Liverpool, L9 7LJ, United Kingdom
  • Pfizer Investigational Site
    York, Y031 8HE, United Kingdom
  • Pfizer Investigational Site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 2, 2005
Start
Sep 2001
Completion
Feb 2006
Last update
Jul 24, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jul 24, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00143143
Lead sponsor
Pfizer
First posted
Sep 2, 2005
Start date
Sep 2001
Completion
Feb 2006
Last update
Jul 24, 2006

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion